Download pdf
Car-T cell therapy: T-immunotherapy application in blood cancer
- 1 University of California Irvine
* Author to whom correspondence should be addressed.
Abstract
Considering the unsuccessful results and lack of sustainable efficiency of previous cancer therapies, T-immunotherapy's clinical success has led to a revolution in cancer treatments. Blood cancers, characterized by abnormal blood cells and metastasis, result in severe health issues and cause high mortality rates. Conventional treatments like chemotherapy and radiation often result in poor prognoses due to cancer cell resistance and have a high relapse rate. This paper focuses on how Chimeric Antigen Receptor (CAR)-T cell therapy removes tumor cancerous cells with genetically engineered T-cells. The specific targeting ability of T-cell allows it to overcome the difficulty unresolved by traditional treatments. Despite its significant progress, CAR-T cell therapy also experienced new challenges brought by its specific treatment: cytokine release syndrome and logistical complexities. This paper provides a comprehensive review of T-cell therapy's novel enhancement of blood cancers, including its mechanisms, applications, and side effects after therapy. Various data underline T-cell therapy's potential as a novel cancer treatment, though further research is needed to address its limitations and improve patient outcomes. This research paper provides valuable insights into CAR-T therapy application, minimizing toxicity, and expanding its applicability, offering a reference for future research. Unresolved issues such as managing side effects and improving accessibility continue to be focused for future investigation.
Keywords
Car-T therapy, T-immunotherapy, cytokine release syndrome
[1]. US Food and Drug Administration 2017 FDA briefing document: Oncologic Drugs Advisory Committee meeting; BLA 125646; Tisagenlecleucel Novartis Pharmaceuticals Corporation FDA
[2]. Prasad V 2018 Tisagenlecleucel — the first approved CAR-T-cell therapy: Implications for payers and policy makers Nature Reviews Clinical Oncology 15 1 11–12
[3]. Cheng H Qiu Y Xu Y et al 2023 Extracellular acidosis restricts one-carbon metabolism and preserves T cell stemness Nature Metabolism 5 314–330
[4]. US Food and Drug Administration 2017 FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome FDA
[5]. Dunphy K Dowling P Bazou D & O’Gorman P 2021 Current methods of post-translational modification analysis and their applications in blood cancers Cancers 13 8 1930
[6]. Cleveland Clinic (n.d.) T-Cells. Retrieved from https://my.clevelandclinic.org/health/body/24630-t-cells
[7]. Feins S Kong W Williams E F et al 2019 An introduction to chimeric antigen receptor CAR T‐Cell immunotherapy for human cancer American Journal of Hematology 94 S1
[8]. Ali S Kjeken R Niederlaender C Markey G et al 2019 The European Medicines Agency review of kymriah tisagenlecleucel for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma The Oncologist 25 2
[9]. Schuster S J Bishop M R Tam C S et al 2019 Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma New England Journal of Medicine 380 1 45–56
[10]. Kymriah (n.d.) Understanding kymriah. Retrieved from https://www.us.kymriah.com/diffuse-large-b-cell-lymphoma-adults/about-kymriah/understanding-kymriah/
[11]. Siegler E L & Kenderian S S 2020 Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: Insights into mechanisms and novel therapies Frontiers in Immunology 11
[12]. Murthy H Iqbal M Chavez J C & Kharfan-Dabaja M A 2019 Cytokine release syndrome: Current perspectives ImmunoTargets and Therapy 8 43–52
[13]. Hirayama A V & Turtle C J 2019 Toxicities of CD19 CAR-T cell immunotherapy American Journal of Hematology 94 S1 S42–S49
[14]. Zhao Z Condomines M van der Stegen S J Perna F Kloss C C Gunset G et al 2015 Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells Cancer Cell 28 4 415–428
[15]. Rajasekaran S Kruse K Kovey K Davis A T Hassan N E Ndika A N et al 2014 Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children Pediatric Critical Care Medicine 15 5 401–408
[16]. Wohlfarth P Agis H Gualdoni G A Weber J Staudinger T Schellongowski P et al 2019 Interleukin 1 receptor antagonist anakinra intravenous immunoglobulin and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis Journal of Intensive Care Medicine 34 9 723–731
[17]. Wolf B Zimmermann S Arber C Irving M Trueb L & Coukos G 2019 Safety and tolerability of adoptive cell therapy in cancer Drug Safety 42 3 315-334
[18]. Hunter B D & Jacobson C A 2019 CAR T-cell associated neurotoxicity: Mechanisms clinicopathologic correlates and future directions Journal of the National Cancer Institute 111 7 646–654
Cite this article
Tan,A.J. (2024). Car-T cell therapy: T-immunotherapy application in blood cancer. Theoretical and Natural Science,48,34-39.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Environmental Geoscience and Earth Ecology
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).